{
  "meta": {
    "timestamp": "2025-01-06T14:17:33.942992",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Tarsus Pharmaceuticals Inc.",
      "symbol": "TARS",
      "analysis": {
        "historical": {
          "risk_score": 65,
          "key_risks": [
            "Regulatory Risks: Dependence on FDA and international regulatory approvals for TP-03 and other pipeline candidates.",
            "Market Competition: High competition in ophthalmology and dermatology sectors.",
            "Financial Sustainability: Reliance on external funding as a clinical-stage company.",
            "Dependence on TP-03: Near-term success heavily tied to TP-03's commercialization.",
            "Manufacturing Dependencies: Reliance on third-party manufacturers for quality control and scalability."
          ],
          "controversies": [],
          "environmental_issues": [],
          "social_issues": [
            "Ethical Commitment: Emphasis on patient-centric values and advancing science through education and research."
          ],
          "governance_issues": [],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance of ...",
              "snippet": "Currently, there are no FDA-approved pharmacological prophylactic options for Lyme disease. About Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. FDA approval delays",
              "retrieved_at": "2025-01-06T21:17:07.936485+00:00",
              "published_date": null,
              "source_hash": "a0c9a7f60b9a1cd8a1041f18e3ac75ce"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance of ...",
              "snippet": "About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. FDA approval delays",
              "retrieved_at": "2025-01-06T21:17:07.936550+00:00",
              "published_date": null,
              "source_hash": "6e4b46d01efb863f969690e9c9688022"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance of - GlobeNewswire",
              "snippet": "Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance of Investigational New Drug Application for TP-05 for Lyme Disease Prevention May 04, 2021 16:05 ET | Source: Tarsus Pharmaceuticals, Inc",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. FDA approval delays",
              "retrieved_at": "2025-01-06T21:17:07.936561+00:00",
              "published_date": null,
              "source_hash": "a1b045afaa36700adc1941d8563b741e"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals, Inc. - AnnualReports.com",
              "snippet": "XDEMVYTM (lotilaner ophthalmic solution) 0.25% is FDA approved ... Tarsus Pharmaceuticals, Inc. Most Recent Annual Report. MOST RECENT 2023 Annual Report and Form 10K. View PDF View Form 10K (HTML) Older/Archived Annual Reports. 2022 Annual Report View Annual Report Download.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. FDA approval delays",
              "retrieved_at": "2025-01-06T21:17:07.936569+00:00",
              "published_date": null,
              "source_hash": "a942bfa4b2098601f3495b16d83c7219"
            },
            {
              "url": "",
              "title": "Investors & News - Tarsus Pharmaceuticals",
              "snippet": "Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. ... 0.25%, is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-03 for the treatment of Meibomian Gland Disease, which is currently being studied in a ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. FDA approval delays",
              "retrieved_at": "2025-01-06T21:17:07.936576+00:00",
              "published_date": null,
              "source_hash": "e5168af8a2c86f86681f8f8ef5348d22"
            },
            {
              "url": "",
              "title": "TP-05 - Tarsus",
              "snippet": "Currently, there is no FDA-approved pharmacologic option for preventing Lyme disease. 2. TP-05 is 1,2: ... Tarsus Pharmaceuticals, Inc. initiates phase 1 Callisto trial of TP-05, a novel, oral, non-vaccine therapeutic for the prevention of Lyme disease. News release. Tarsus Pharmaceuticals, Inc. June 16, 2021.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. FDA approval delays",
              "retrieved_at": "2025-01-06T21:17:07.936584+00:00",
              "published_date": null,
              "source_hash": "3366acf9f552eb8e1b85abc5c56d3e81"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals | TARS Stock Price, Company Overview & News - Forbes",
              "snippet": "Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:17:17.496675+00:00",
              "published_date": null,
              "source_hash": "5c488fffc787f39c751525b38357aaeb"
            },
            {
              "url": "",
              "title": "Tarsus Pharma: Despite Dropping After FDA Approval, 2 Catalysts Still ...",
              "snippet": "Tarsus Pharmaceuticals had $201.2 million in cash as of March 31, 2023, and believes it has enough cash to fund its operations for 12 months; With cash projection and FDA approval of XDEMVY in, it ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. FDA approval delays",
              "retrieved_at": "2025-01-06T21:17:07.936597+00:00",
              "published_date": null,
              "source_hash": "7ea15c965f70068628e85f452a7141e6"
            },
            {
              "url": "",
              "title": "Tarsus Pharma Announces FDA Approval Of XDEMVY For Treatment ... - Nasdaq",
              "snippet": "(RTTNews) - Tarsus Pharmaceuticals, Inc. (TARS) announced the FDA approved XDEMVY 0.25% for the treatment of Demodex blepharitis. XDEMVY is the first and only FDA approved treatment to directly ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. FDA approval delays",
              "retrieved_at": "2025-01-06T21:17:07.936603+00:00",
              "published_date": null,
              "source_hash": "c6bf051e17048baf194a2dd5ea278b1c"
            },
            {
              "url": "",
              "title": "News Release - Tarsus Pharmaceuticals",
              "snippet": "The first and only FDA-approved treatment for Demodex blepharitis. XDEMVY\u00ae ... 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. FDA approval delays",
              "retrieved_at": "2025-01-06T21:17:07.936609+00:00",
              "published_date": null,
              "source_hash": "c9f0e6f6cef294f59b472de8306591e6"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals",
              "snippet": "Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03 ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:17:19.644707+00:00",
              "published_date": "2025-01-03T00:00:00+00:00",
              "source_hash": "e364e470d84883418fefddeb2bbf0fd3"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of \"Buy\" by Brokerages",
              "snippet": "Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has been assigned a consensus recommendation of \"Buy\" from the seven analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation,",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:17:19.644808+00:00",
              "published_date": "2024-12-24T07:18:00+00:00",
              "source_hash": "2c7e612e2633fb3f498e8d51c2a1e9a1"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceutical - Eye Care Therapeutics",
              "snippet": "Since the Trend Seeker signaled a buy on 9/4 the stock gained 48.35%. TARS Price vs Daily Moving Averages: Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:17:19.644798+00:00",
              "published_date": "2025-01-02T13:00:03+00:00",
              "source_hash": "edd946b894238619df14f8cf58eb0174"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Call Transcript",
              "snippet": "Tarsus Pharmaceuticals, Inc ... approval in the second half of 2027. Similarly, in the U.S., we remain on track to bring both TPO 4 for rosacea and TPO 5 for prevention of lyme disease to the FDA ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. FDA approval delays",
              "retrieved_at": "2025-01-06T21:17:11.334675+00:00",
              "published_date": "2024-11-15T13:25:00+00:00",
              "source_hash": "dd9ac9c888b853aa81c56aa6d765bb0b"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals: Early Rollout Exceeding Expectations",
              "snippet": "Tarsus Pharmaceuticals is headquartered in Irvine ... The company received its first FDA approval in mid-2023. This is a novel therapeutic for the treatment of blepharitis caused by the ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. FDA approval delays",
              "retrieved_at": "2025-01-06T21:17:11.334689+00:00",
              "published_date": "2024-12-10T15:31:00+00:00",
              "source_hash": "6bd0f2db97f0322de8561cb3576c18a4"
            },
            {
              "url": "",
              "title": "Investors & News - Tarsus Pharmaceuticals",
              "snippet": "Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. investor lawsuits",
              "retrieved_at": "2025-01-06T21:17:12.799077+00:00",
              "published_date": null,
              "source_hash": "12c575a6b1b84834eed87cbf1cda9c56"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals, Inc. (TARS) - Yahoo Finance",
              "snippet": "Find the latest Tarsus Pharmaceuticals, Inc. (TARS) stock quote, history, news and other vital information to help you with your stock trading and investing.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. investor lawsuits",
              "retrieved_at": "2025-01-06T21:17:12.799183+00:00",
              "published_date": null,
              "source_hash": "04ca4b125687c36e94450aaef0ed63ed"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals Inc. - MarketWatch",
              "snippet": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. investor lawsuits",
              "retrieved_at": "2025-01-06T21:17:12.799199+00:00",
              "published_date": null,
              "source_hash": "20129562dac2a10ae680b01eed988fc4"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals, Inc. (TARS) - Stock Analysis",
              "snippet": "Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript. Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Nakasone - Head, Investor Relations Bobby Azamian - Chairman and CEO A...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. investor lawsuits",
              "retrieved_at": "2025-01-06T21:17:12.799210+00:00",
              "published_date": null,
              "source_hash": "011c818bd36bc3e1344a80ac17699cfc"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals, Inc. (TARS) Company Profile & Overview - Stock ...",
              "snippet": "Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:17:17.496733+00:00",
              "published_date": null,
              "source_hash": "f92acf7c1c473bd425ba68699cf90f52"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals Inc TARS Overview - U.S. News",
              "snippet": "Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. ... Investors should keep a keen eye ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. investor lawsuits",
              "retrieved_at": "2025-01-06T21:17:12.799232+00:00",
              "published_date": null,
              "source_hash": "28d3d0c7686bb48af28eef3e35e47e7b"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals Inc. (TARS) Stock Price Today - WSJ",
              "snippet": "View the latest Tarsus Pharmaceuticals Inc. (TARS) stock price, news, historical charts, analyst ratings and financial information from WSJ.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. investor lawsuits",
              "retrieved_at": "2025-01-06T21:17:12.799242+00:00",
              "published_date": null,
              "source_hash": "0b2c2fc06bb98d2ba2a73c25aeb3b69a"
            },
            {
              "url": "",
              "title": "TARS.O - | Stock Price & Latest News | Reuters",
              "snippet": "Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:17:17.496761+00:00",
              "published_date": null,
              "source_hash": "71eba478e18bcf1915dbe788530d883b"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals, Inc. - AnnualReports.com",
              "snippet": "Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. investor lawsuits",
              "retrieved_at": "2025-01-06T21:17:12.799259+00:00",
              "published_date": null,
              "source_hash": "fae2b0e74a55451d03e8c57ced477ac4"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals Inc, TARS:NSQ summary - FT.com",
              "snippet": "Tarsus to Participate in Upcoming Investor Conferences May 29 2024; More TARS:NSQ price moved over -1.33% to 51.75 Dec 02 2024; About the company. Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. investor lawsuits",
              "retrieved_at": "2025-01-06T21:17:12.799269+00:00",
              "published_date": null,
              "source_hash": "36dcaee0d829603927b6a5698467b851"
            },
            {
              "url": "",
              "title": "Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet",
              "snippet": "Tarsus Pharmaceuticals, Inc. (TARS) closed the last trading session ... While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. investor lawsuits",
              "retrieved_at": "2025-01-06T21:17:15.622024+00:00",
              "published_date": "2024-12-11T00:00:00+00:00",
              "source_hash": "676e878e9d42ec676ead6dfed454d7a9"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Call Transcript",
              "snippet": "Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ... I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call. David, you may begin. Thank you.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. investor lawsuits",
              "retrieved_at": "2025-01-06T21:17:15.622037+00:00",
              "published_date": "2024-11-15T13:25:00+00:00",
              "source_hash": "4b5aff20f621bfe00fb5c9302cc92e3f"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals (NASDAQ:TARS) Sets New 12-Month High - Should You Buy?",
              "snippet": "Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) hit a new 52-week high on Monday . The company traded as high as $57.14 and last traded at $56.17, with a volume of 228758 shares.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. investor lawsuits",
              "retrieved_at": "2025-01-06T21:17:15.622063+00:00",
              "published_date": "2024-12-30T19:24:00+00:00",
              "source_hash": "21e5a79fc4916bf2d5b9971209f5acfb"
            },
            {
              "url": "",
              "title": "Home | Tarsus",
              "snippet": "Our Story Serving patient needs is our passion; delivering revolutionary treatments is our mission Our Leadership Our experienced leaders are bound by passion and science Our Values We live our values of commitment, empowerment and teamwork Our Responsibility Advancing a vision for change Medical Affairs We are committed to advancing science and medicine through awareness, education and research",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:17:17.496560+00:00",
              "published_date": null,
              "source_hash": "361cfb45ab488e69ac063225e36de206"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance of ...",
              "snippet": "Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:17:17.496691+00:00",
              "published_date": null,
              "source_hash": "311b37c5cf3ea49bb65d76656b539b0b"
            },
            {
              "url": "",
              "title": "Investors & News - Tarsus Pharmaceuticals",
              "snippet": "Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. ... TP-04 and TP-05 are both currently being studied in Phase 2a clinical trials to evaluate safety, tolerability, and proof-of activity. Stock Information. Minimum 15 minutes delayed. Source: LSEG. News.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:17:17.496702+00:00",
              "published_date": null,
              "source_hash": "d137153938727576193601f15a9c087f"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals, Inc. (TARS) - Yahoo Finance",
              "snippet": "Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:17:17.496713+00:00",
              "published_date": null,
              "source_hash": "05ccaf7a48ebe916947253ce686fbdef"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals, Inc. (TARS) - Stock Analysis",
              "snippet": "Tarsus Pharmaceuticals, Inc.'s Xdemvy, the first FDA-approved treatment for demodex blepharitis, has shown significant efficacy and rapid revenue growth, with $40.8M revenue in Q2 2024. ... TARS has reported positive results from three clinical trials of lotilaner in various formulations. TARS plans to discuss the path forward in these new ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:17:17.496724+00:00",
              "published_date": null,
              "source_hash": "188dd0cd901048e50936ac5bf5c4a081"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals Inc TARS Overview - U.S. News",
              "snippet": "Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:17:17.496744+00:00",
              "published_date": null,
              "source_hash": "7df100f3c51377f21a42df8e029cc02d"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals, Inc. - AnnualReports.com",
              "snippet": "Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:17:17.496752+00:00",
              "published_date": null,
              "source_hash": "28fa49894fd74b5ad2239e4854f1e99b"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Call Transcript",
              "snippet": "Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ... we are very excited about the positive data from the Ersa and Rare trials that were presented last week at the American Academy of Optometry or ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:17:19.644785+00:00",
              "published_date": "2024-11-15T13:25:00+00:00",
              "source_hash": "fb352d09a5ce45810b161d6a67451361"
            },
            {
              "url": "",
              "title": "Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?",
              "snippet": "The market expects Tarsus Pharmaceuticals, Inc. (TARS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Tarsus Pharmaceuticals Inc. Tarsus Pharmaceuticals Inc. clinical trial controversies",
              "retrieved_at": "2025-01-06T21:17:19.644818+00:00",
              "published_date": "2024-11-07T00:00:00+00:00",
              "source_hash": "00c21e138118a7f08a3a680c48f95643"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Tarsus Pharmaceuticals Inc. FDA approval delays",
              "rationale": "Investigate potential risks related to regulatory delays for TP-03 and other pipeline products",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Tarsus Pharmaceuticals Inc. investor lawsuits",
              "rationale": "Check for any legal disputes or investor concerns regarding financial performance or disclosures",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Tarsus Pharmaceuticals Inc. clinical trial controversies",
              "rationale": "Explore any ethical concerns or controversies related to the conduct of clinical trials for TP-03 or other products",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:17:33.942999",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}